|
|||||
|
|
| 吉西他滨联合希罗达治疗晚期胰腺癌疗效观察 | |
| 引用本文： | 赵彩霞,李军,刘锁利,刘静琴,贾喜花,尚红娟. 吉西他滨联合希罗达治疗晚期胰腺癌疗效观察[J]. 中国肿瘤临床与康复, 2005, 12(6): 558-560 |
| 作者姓名： | 赵彩霞 李军 刘锁利 刘静琴 贾喜花 尚红娟 |
| 作者单位： | 1. 保定市第一医院肿瘤科,071000 2. 保定市第一中心医院肿瘤科 3. 江西九江市肿瘤医院 |
| 摘 要： | 目的观察吉西他滨加希罗达方案治疗晚期胰腺癌的客观疗效及其临床受益反应(CBR).方法对26例晚期胰腺癌患者给予此方案化疗3个周期,按WHO标准评定疗效及不良反应,同时综合评估临床受益率指标:疼痛、体力状况及体重变化.结果有效率(CR PR)为29.1%,参照CBR综合指标,CBR率66.7%,不良反应主要为骨髓抑制和胃肠反应.结论吉西他滨加希罗达是治疗晚期胰腺癌的一种安全有效的化疗方案. |
| 关 键 词： | 胰腺肿瘤/化学疗法 吉西他滨 希罗达 |
| 文章编号： | 1005-8664(2005)06-0558-03 |
| 修稿时间： | 2005-04-07 |
Evaluation of the clinical efficacy of chemotherapy with gemcitabine and xeloda in treatment of advanced pancreatic cancer |
|
| ZHAO Cai-xia,LI Jun,LIU Suo-li,et al. Evaluation of the clinical efficacy of chemotherapy with gemcitabine and xeloda in treatment of advanced pancreatic cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2005, 12(6): 558-560 | |
| Authors: | ZHAO Cai-xia LI Jun LIU Suo-li et al |
| Abstract: | Objective To evaluate the clinical efficacy and CBR of chemotherapy with gemcitabine and xeloda in treatment of advanced pancreaticcancer.Method Twenty-six patients was treated with this regimen for 3 cycle.The efficacyand side effect were evaluated according to the WHO criterion,and the indexes of CBR includingache,physical strength and body weight were also evaluated.Result Response rate(CR+PR) was 29.1%.With neference to the integrated indexes of CBR,the CBR rate 66.7%.The adverse reaction was mainly bone marrow suppression and gastroenteric side effects.Conclusion Gemcitabine combined with xeloda for treatment of advanced pancreaticcancer is a kind of effective and safe regimen of chemotherapy. |
| Keywords: | Pancreatic neoplasms/chemotherapy Gemcitabine Xeloda |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |